Product
LP-168
Aliases
LP-168 tablet, NWP-775
5 clinical trials
11 indications
Indication
Multiple SclerosisIndication
Neuromyelitis Optica Spectrum DisorderIndication
mantle cell lymphomaIndication
Waldenstrom MacroglobulinemiaIndication
Follicular LymphomaIndication
Diffuse Large B-Cell LymphomaIndication
Marginal Zone LymphomaIndication
Hairy Cell LeukemiaIndication
Mantle Cell LymphomaIndication
B-cell LymphomaClinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LP-168 Following Single and Multiple Oral Administration to Healthy VolunteersStatus: Completed, Estimated PCD: 2022-11-20
Clinical trial
A Randomized, Two-period, Two-sequence Two-treatment Crossover Design Food Effect Study to Evaluate the Pharmacokinetic Profile of LP-168 Tablets in Healthy Subjects After Single Oral Administration Under Fasted and Fed ConditionsStatus: Completed, Estimated PCD: 2023-08-21
Clinical trial
A Phase I, Multicenter, Open-Label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-168 in Subjects With Relapsed or Refractory B-cell Malignancies.Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
An Open Label, Single Arm, Multicenter Phase II Study of the Efficacy and Safety of LP-168 Monotherapy for Recurrent or Refractory Mantle Cell LymphomaStatus: Recruiting, Estimated PCD: 2024-02-28
Clinical trial
A Phase 1 Open-Label Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of LP-168 in Adult Patients With Relapse or Refractory B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2023-12-31